Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 4.56 USD 0.22%
Market Cap: 371.1m USD
Have any thoughts about
Codexis Inc?
Write Note

Codexis Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Codexis Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Codexis Inc
NASDAQ:CDXS
Accrued Liabilities
$20.9m
CAGR 3-Years
-9%
CAGR 5-Years
12%
CAGR 10-Years
17%
Thermo Fisher Scientific Inc
NYSE:TMO
Accrued Liabilities
$5.2B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accrued Liabilities
$2.9B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Accrued Liabilities
$364.6m
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Accrued Liabilities
$573m
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
-2%
IQVIA Holdings Inc
NYSE:IQV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Codexis Inc
Glance View

Market Cap
371.1m USD
Industry
Life Sciences Tools & Services

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

CDXS Intrinsic Value
2.95 USD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Codexis Inc's Accrued Liabilities?
Accrued Liabilities
20.9m USD

Based on the financial report for Sep 30, 2024, Codexis Inc's Accrued Liabilities amounts to 20.9m USD.

What is Codexis Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
17%

Over the last year, the Accrued Liabilities growth was -20%. The average annual Accrued Liabilities growth rates for Codexis Inc have been -9% over the past three years , 12% over the past five years , and 17% over the past ten years .

Back to Top